Monopar Therapeutics (MNPR) Research & Development: 2017-2019
Historic Research & Development for Monopar Therapeutics (MNPR) over the last 3 years, with Dec 2019 value amounting to $583,778.
- Monopar Therapeutics' Research & Development rose 12.05% to $583,778 in Q4 2019 from the same period last year, while for Dec 2019 it was $2.0 million, marking a year-over-year increase of 24.16%. This contributed to the annual value of $2.0 million for FY2019, which is 10.94% up from last year.
- According to the latest figures from Q4 2019, Monopar Therapeutics' Research & Development is $583,778, which was up 165.54% from $219,846 recorded in Q3 2019.
- In the past 5 years, Monopar Therapeutics' Research & Development registered a high of $835,600 during Q1 2019, and its lowest value of $133,736 during Q1 2017.
- Its 3-year average for Research & Development is $374,111, with a median of $310,454 in 2017.
- In the last 5 years, Monopar Therapeutics' Research & Development skyrocketed by 241.82% in 2018 and then dropped by 27.61% in 2019.
- Over the past 3 years, Monopar Therapeutics' Research & Development (Quarterly) stood at $309,315 in 2017, then skyrocketed by 68.43% to $520,982 in 2018, then climbed by 12.05% to $583,778 in 2019.
- Its Research & Development stands at $583,778 for Q4 2019, versus $219,846 for Q3 2019 and $329,294 for Q2 2019.